Silicon Laboratories Inc. | |||
Condensed Consolidated Statements of Cash Flows | |||
(In thousands) | |||
(Unaudited) | |||
| |||
| Year Ended | ||
| December 30,
|
| December 31,
|
Operating Activities |
|
|
|
Net income (loss) | $ (34,516) |
| $ 91,402 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities of continuing operations: |
|
|
|
Depreciation of property and equipment | 25,707 |
| 22,524 |
Amortization of other intangible assets | 25,374 |
| 34,071 |
Amortization of debt discount and debt issuance costs | 960 |
| 2,003 |
Loss on extinguishment of convertible debt | -- |
| 3 |
Stock-based compensation expense | 48,208 |
| 60,510 |
Equity-method (earnings) loss | 16,030 |
| (3,400) |
Deferred income taxes | (11,815) |
| (18,240) |
Changes in operating assets and liabilities: |
|
|
|
Accounts receivable | 42,142 |
| 26,876 |
Inventories | (93,398) |
| (51,044) |
Prepaid expenses and other assets | (10,733) |
| (31,240) |
Accounts payable | (25,644) |
| 36,797 |
Other current liabilities and income taxes | (37,793) |
| (12,738) |
Deferred revenue and returns liability | (4,663) |
| (7,069) |
Other non-current liabilities | 29,793 |
| (9,181) |
Net cash provided by (used in) operating activities of continuing operations | (30,348) |
| 141,274 |
|
|
|
|
Investing Activities |
|
|
|
Purchases of marketable securities | (103,485) |
| (607,237) |
Sales of marketable securities | 395,565 |
| 223,354 |
Maturities of marketable securities | 200,530 |
| 650,946 |
Purchases of property and equipment | (22,282) |
| (26,525) |
Purchases of other assets | (520) |
| -- |
Net cash provided by investing activities of continuing operations | 469,808 |
| 240,538 |
|
|
|
|
Financing Activities |
|
|
|
Proceeds from issuance of debt | 80,000 |
| -- |
Payments on debt | (571,157) |
| (21) |
Repurchases of common stock | (217,137) |
| (883,424) |
Payment of taxes withheld for vested stock awards | (18,189) |
| (15,387) |
Proceeds from the issuance of common stock | 14,612 |
| 11,779 |
Net cash used in financing activities of continuing operations | (711,871) |
| (887,053) |
|
|
|
|
Discontinued Operations |
|
|
|
Operating activities | -- |
| (69,467) |
Net cash used in discontinued operations | -- |
| (69,467) |
|
|
|
|
Decrease in cash and cash equivalents | (272,411) |
| (574,708) |
Cash and cash equivalents at beginning of period | 499,915 |
| 1,074,623 |
Cash and cash equivalents at end of period | $ 227,504 |
| $ 499,915 |